Amezosvatein
Alternative Names: CRV-101; Shingles vaccine - Curevo VaccineLatest Information Update: 18 Oct 2024
Price :
$50 *
At a glance
- Originator Mogam Biotechnology Research Institute
- Developer Curevo Vaccine; GC Biopharma; Mogam Biotechnology Research Institute
- Class Protein vaccines; Subunit vaccines; Synthetic vaccines; Varicella vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Herpes zoster
Most Recent Events
- 16 Oct 2024 Adverse events and immunogenicity data from a phase II trial in Herpes zoster released by Curevo Vaccine
- 16 Oct 2024 Curevo Vaccine plans a phase-III trial for Herpes zoster (prevention) in 2025 (IM, injection)
- 07 Jan 2024 Adverse events and efficacy data from a phase II trial in Herpes zoster released by Curevo Vaccine